In vivo and in vitro evidence of growth hormone-releasing factor-like produced locally in the adenohypophyseal cells of the rat

In vitro and in vivo evidence for direct dopaminergic inhibition of VIP-immunoreactive pituitary cells

In order to establish whether dopamine is involved in the regulation of immunocytochemical expression of VIP in pituitary cells, in vivo and in vitro studies were carried out on male rats after treatment with haloperidol and dopamine, respectively. In the in vivo studies, following intraventricular (third ventricle) administration of haloperidol, an increase in the total number of VIP-immunoreactive cells (p < 0.05) was observed; additionally, the cellular, cytoplasmic and nuclear areas were increased (p < 0.01). The in vitro studies demonstrated that dopamine induces a significant decrease (p < 0.05) in the total number of VIP-immunoreactive cells, which were smaller than the cells from the control dishes, because dopamine induces a significant decrease in their cellular, cytoplasmic and nuclear areas (p < 0.01). These results support the hypothesis that dopamine is a physiological inhibitor of pituitary VIP expression and suggest that dopamine modulates the auto- or paracrine effects of VIP in the rat pituitary.

Bioactive peptides in anterior pituitary cells

The anterior pituitary (AP) has been shown to contain a wide variety of bioactive peptides: brain-gut peptides, growth factors, hypothalamic releasing factors, posterior lobe peptides, opioids, and various other peptides. The localization of most of these peptides was first established by immunocytochemical methods and some of the peptides were localized in identified cell types. Although intracellular localization of a peptide may be the consequence of internalization from the plasma compartment, there is evidence for local synthesis of most of these peptides in the AP based on the identification of their messenger-RNA (mRNA). In several cases the release of the peptide from the AP cell has been shown and regulation of synthesis, storage and release have also been described. Because the amount of most of the AP peptides is very low (except for POMC peptides and galanin), endocrine functions are not expected. There is more evidence for paracrine, autocrine, or intracrine roles in growth, differentiation, and regeneration, or in the control of hormone release. To demonstrate such functions, in vitro AP experiments have been designed to avoid the interference of hypothalamic or peripheral hormones. The strategy is first to show a direct effect of the peptide after adding it to the in vitro system and, secondly, to explore if the endogenous AP peptide has a similar action by using blockers of peptide receptors or antisera immunoneutralizing the peptide.

Immunocytochemical evidence of hypothalamic regulation of adenohypophyseal VIP in the male rat

In order to check whether hypothalamic stimulatory or inhibitory factors exert any kind of modulation on the morphology of VIP-immunoreactive cells in the rat hypophysis, the transport of these towards the hypophyseal portal system was blocked by intraventricular administration of colchicine in adult male rats, thereafter performing a morphometric study after characterizing the VIP-immunoreactive adenohypophyseal cells by immunocytochemical techniques. Colchicine administration led to a significant increase (p < 0.01) in the number of reactive cells observed. These cells were characterized by a larger cellular area (p < 0.01), owing to increases in nuclear area (p < 0.05) and cytoplasmic area (p < 0.05). Their morphology became more regular, with a predominance of polygonal and oval cells. The results suggest that the VIP-reactive cells of the rat hypophysis are subject to a hypothalamic inhibitory influence and their activity increasing when the hypothalamic effect is interrupted by intraventricular administration of colchicine.